Targeted Therapy With — Dementia or Mental Illness

Patients with dementia can consent to their own treatment if they have the capacity to understand what is being decided. Capacity is assessed for each specific decision and can fluctuate — someone may be able to agree to a blood test but not to a complex treatment course. The oncologist will assess this, often with input from the neurologist or a psychiatrist. If the patient does not have capacity, a legal representative — typically the nearest relative or a person holding healthcare power of attorney — makes the decision in the patient's best interests. Indian law provides a framework for this, and the hospital's patient care team can advise your family on the process.

Some targeted agents cause cognitive side effects — difficulty concentrating, fatigue, or episodes of confusion — that can be harder to distinguish in a patient who already has dementia. Whether this worsens the underlying dementia is less clear, and the evidence is limited because patients with cognitive impairment are often excluded from clinical trials. What the team will do is record a baseline of the patient's usual function at the start and monitor for any change from that point. A sudden worsening in confusion or behaviour should be reported to the oncology team rather than waiting for the next scheduled appointment.

A caregiver-managed system is the standard approach — a weekly pill organiser prepared by the caregiver or pharmacist, not by the patient. For patients in memory care or with a paid carer, the oncology team should provide written instructions about each tablet and what to do if a dose is missed. Most targeted agents have a specific rule about missed doses — usually skip the missed dose rather than double up — but this differs between drugs, so confirm the rule for your specific medication at the start and keep it written down near the pills.

Yes — and the oncologist needs to know about the psychiatric medication too. Both conversations should happen before the first dose, not at the next routine review. Interactions between some psychiatric medications and targeted agents can be significant enough to influence the choice of agent or the monitoring plan. If the oncologist and psychiatrist are at different hospitals, ask for a written medication summary from each to share with the other. Neither team can make safe decisions without knowing what the other has prescribed.

Historically, many trials have excluded patients with psychiatric diagnoses or cognitive impairment, and ASCO and other bodies have noted this as a gap that needs to change. It means the evidence base for this population is thinner than for others, and your oncologist may be working from general pharmacological principles about interactions and monitoring rather than trial data specific to this group. That is an honest limitation to name — it is also a reason for more careful monitoring during treatment, not a reason to withhold treatment.

Some targeted agents can cause or worsen depression, anxiety, irritability, or mood swings — this is a recognised category of side effect, not a sign that the cancer is progressing. Report any significant change in mood or behaviour to the oncology team promptly. The team will assess whether the symptom is related to the targeted therapy, the underlying psychiatric illness, or an interaction between the two medications. Dose adjustment or a switch to an alternative agent can often resolve it. Do not stop the targeted therapy on your own — the oncologist needs to assess the symptom before any change is made.

In most cases, yes. The key step is checking for interactions between the specific antipsychotic and the specific targeted agent before starting — this is a drug-by-drug assessment, not a general one. Some antipsychotics affect the liver enzyme pathways that also process targeted therapies, which can raise or lower the level of the cancer drug in the blood. Some antipsychotics also affect heart rhythm, and a small number of targeted agents carry a similar risk — the team may request an ECG before and during treatment in that situation. Neither consideration rules out treatment, but both need to be assessed in advance.

At CION, targeted therapy is delivered as day care, which means the caregiver is present at every appointment and can speak directly with the treating team. Before starting, the oncologist will request coordination with the patient's psychiatrist or neurologist and can arrange for a pharmacist review of the full medication list. Families are asked to bring a written list of every medication and supplement the patient is taking — including anything from a traditional or Ayurvedic practitioner — because these can also interact with targeted agents. If the caregiver has concerns between appointments, the treating centre has a contact pathway for queries that cannot wait.